SPLEEN TO SCREEN
LIVE

Serial Number

79227419

Owner

Merus N.V.

Attorney

Max Vern

Filing Date

Jul 21, 2017

Add to watchlist:

No watchlists yet
View on USPTO

SPLEEN TO SCREEN Trademark

Serial Number: 79227419 • Registration: 5830546

SPLEEN TO SCREEN is a trademark filed by Merus N.V. on July 21, 2017. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 45 (Legal & Security Services). The application is currently registered and active.

Owner Contact Info

Merus N.V. (16 trademarks)

Uppsalalaan 17,

Entity Type: 32

Merus B.V. (4 trademarks)

Padualaan 8

Entity Type: 99

Trademark Details

Filing Date

July 21, 2017

Registration Date

August 13, 2019

Published for Opposition

May 28, 2019

Goods & Services

[ Biochemical products used in the medical and pharmaceutical industry and in science, in particular antibodies in the nature of protein mixtures for rapidly screening panels of target-specific antibodies for the downstream production of, and for the manufacture of, mono and multispecific biologics being biological preparations in the fields of immuno-oncology and auto-immune diseases ]

Services of biochemists, namely, scientific and medical laboratory services in the nature of efficient screening of antibodies in the nature of protein mixtures for the generation of mono and multispecific biologics; [ services of bacteriologic and biochemical laboratories, namely, research in the field of biochemistry; professional advice relating to biochemistry; ] conducting scientific and industrial research using laboratory techniques, [ namely, the extraction, fragmentation, cloning, transformation, isolation, concatenation, complementing, selection, identification and compilation of cells and genetic materials in the nature of DNA and preparing related professional reports; professional advice relating to scientific and industrial research using laboratory techniques, namely, the extraction, fragmentation, cloning, transformation, isolation, concatenation, complementing, selection, identification and compilation of cells and genetic materials in the nature of DNA and the preparation of related professional reports; ] reviewing and analyzing anti-bodies [ in the nature of protein mixtures used in the medical and pharmaceutical industry and in science and the preparation of related professional reports for scientists, engineers, analysts and laboratory assistants and technicians for industry and government services; scientific and industrial research, in particular in the field of the aforementioned anti-bodies, namely, anti-bodies in the nature of protein mixtures; research and development of new products for others, in particular anti-bodies in the nature of protein mixtures; chemical and laboratory research services, namely, performing extraction, fragmentation, cloning, transformation, isolation, concatenation, complementing, selection, identification and compilation of cells and genetic materials in the nature of DNA and the preparation of related professional reports; consultancy relating to chemical and laboratory research services, namely, the performance of extraction, fragmentation, cloning, transformation, isolation, concatenation, complementing, selection, identification and compilation of cells and genetic materials in the nature of DNA and the preparation of related professional reports ]

[ Pharmaceutical and veterinary preparations prepared with antibodies in the nature of protein mixtures used in the medical and pharmaceutical industry and in science for the treatment of cancer and other therapeutic indications, namely, for the generation of mono and multispecific biologics being biological preparations in the fields of immuno-oncology and auto-immune diseases]

[ Medical services; veterinary services; genetic testing of research animals, in particular of transgenic mice for research purposes ]

[ Legal services; legal services relating to exploitation of intellectual property rights; licensing of intellectual property rights; legal advisory services in the aforementioned fields, namely, exploitation of intellection property rights and licensing of intellectual property rights, concerning rapid screening of panels of target-specific antibodies for the downstream production of, and for the manufacture of, mono and multispecific biologics in the fields of immuno-oncology and auto-immune diseases ]

Filing History

LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
Jul 28, 2026 LIMN
NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED
Jun 11, 2026 NA75
REGISTERED - PARTIAL SEC. 71 ACCEPTED & SEC. 15 ACK.
Jun 11, 2026 C75P
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Jun 1, 2026 APRE
TEAS CHANGE OF CORRESPONDENCE RECEIVED
May 28, 2026 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
May 28, 2026 ECDR
TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED
May 28, 2026 EWOR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
May 28, 2026 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
May 28, 2026 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
May 28, 2026 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
May 28, 2026 COAR
RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED
May 7, 2026 RHRD
CHANGE OF OWNER RECEIVED FROM IB
Mar 19, 2026 CHLD
TEAS SECTION 71 & 15 RECEIVED
Feb 13, 2026 ES75
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Feb 9, 2026 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Feb 9, 2026 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Feb 9, 2026 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Feb 9, 2026 REAP
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Aug 13, 2024 REM3
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Jul 30, 2023 EWAF
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jul 30, 2023 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Jul 30, 2023 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jul 30, 2023 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jul 30, 2023 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Jul 30, 2023 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Jul 30, 2023 COAR
FINAL DECISION TRANSACTION PROCESSED BY IB
Dec 13, 2019 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Nov 26, 2019 FICS
FINAL DISPOSITION PROCESSED
Nov 26, 2019 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Nov 13, 2019 FICR
REGISTERED-PRINCIPAL REGISTER
Aug 13, 2019 R.PR
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Aug 9, 2019 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jul 24, 2019 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Jul 24, 2019 OPNR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 28, 2019 NPUB
PUBLISHED FOR OPPOSITION
May 28, 2019 PUBO
NOTIFICATION PROCESSED BY IB
May 24, 2019 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
May 8, 2019 OPNS
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 8, 2019 NONP
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
May 8, 2019 OP2R
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 19, 2019 CNSA
EXAMINER'S AMENDMENT ENTERED
Apr 19, 2019 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Apr 19, 2019 GNEN
EXAMINERS AMENDMENT E-MAILED
Apr 19, 2019 GNEA
EXAMINERS AMENDMENT -WRITTEN
Apr 19, 2019 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 3, 2019 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 3, 2019 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 3, 2019 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Oct 9, 2018 GNRN
NON-FINAL ACTION E-MAILED
Oct 9, 2018 GNRT
NON-FINAL ACTION WRITTEN
Oct 9, 2018 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 14, 2018 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 14, 2018 CRFA
ASSIGNED TO LIE
Sep 14, 2018 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 5, 2018 TROA
REFUSAL PROCESSED BY IB
Mar 24, 2018 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Mar 8, 2018 RFCS
REFUSAL PROCESSED BY MPU
Mar 8, 2018 RFRR
APPLICATION FILING RECEIPT MAILED
Mar 6, 2018 MAFR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Mar 2, 2018 RFCR
NON-FINAL ACTION WRITTEN
Mar 1, 2018 CNRT
ASSIGNED TO EXAMINER
Feb 28, 2018 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 28, 2018 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Feb 22, 2018 REPR